Rein Therapeutics, Inc. SEC filings RNTX
Rein Therapeutics, Inc. has 525 filings in SEC EDGAR's recent list, going back to Dec 3, 2007. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | May 4, 2026 | — |
| S-1 | Registration statement | Apr 28, 2026 | — |
| S-1 | Registration statement | Sep 3, 2025 | — |
| 424B5 | Prospectus supplement | Jul 30, 2025 | — |
| 424B5 | Prospectus supplement | Jul 30, 2025 | — |
| S-3 | Shelf registration | May 16, 2025 | — |
| 424B5 | Prospectus supplement | May 15, 2025 | — |
| 424B5 | Prospectus supplement | Jul 26, 2024 | — |
| 424B5 | Prospectus supplement | Jul 26, 2024 | — |
| 424B5 | Prospectus supplement | May 1, 2024 | — |
| S-8 | Employee stock plan registration | May 1, 2024 | — |
| FWP | Free writing prospectus | May 1, 2024 | — |
| S-8 | Employee stock plan registration | Jan 29, 2024 | — |
| S-3 | Shelf registration | Jan 29, 2024 | — |
| 424B5 | Prospectus supplement | Jun 21, 2022 | — |
| S-3 | Shelf registration | Jun 8, 2022 | — |
| 424B5 | Prospectus supplement | Apr 15, 2022 | — |
| S-8 | Employee stock plan registration | Aug 11, 2021 | — |
| S-8 | Employee stock plan registration | Mar 24, 2021 | — |
| S-3 | Shelf registration | Jan 29, 2021 | — |
| 424B5 | Prospectus supplement | Jan 29, 2021 | — |
| 424B5 | Prospectus supplement | Jan 7, 2021 | — |
| 424B5 | Prospectus supplement | Dec 30, 2020 | — |
| 424B3 | Prospectus | Oct 15, 2020 | — |
| S-1 | Registration statement | Oct 5, 2020 | — |
| 424B5 | Prospectus supplement | Sep 25, 2020 | — |
| S-3 | Shelf registration | Aug 11, 2020 | — |
| 424B5 | Prospectus supplement | Jun 5, 2020 | — |
| 424B5 | Prospectus supplement | Jun 3, 2020 | — |
| 424B5 | Prospectus supplement | Jun 3, 2020 | — |
| S-8 | Employee stock plan registration | Mar 30, 2020 | — |
| POS AM | Filing | Jul 15, 2019 | — |
| S-3/A | Filing | Jul 1, 2019 | — |
| S-1/A | Amended registration statement | May 13, 2019 | — |
| S-1 | Registration statement | May 1, 2019 | — |
| S-8 | Employee stock plan registration | Mar 29, 2019 | — |
| S-3 | Shelf registration | Aug 7, 2018 | — |
| S-8 | Employee stock plan registration | May 9, 2018 | — |
| S-8 | Employee stock plan registration | Jul 5, 2017 | — |
| 424B4 | Prospectus | Jun 29, 2017 | — |
| S-1/A | Amended registration statement | Jun 19, 2017 | — |
| S-1 | Registration statement | Jun 2, 2017 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc. (until Dec 9, 2024); AILERON THERAPEUTICS INC (until Mar 29, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.